Rifampicin and its derivatives: stability, disposition, and affinity towards pregnane X receptor employing 2D and 3D primary human hepatocytes
Authors/Creators
- 1. Charles University, Faculty of Pharmacy in Hradec Kralove
Description
Rifampicin is a model ligand of the pregnane X receptor (PXR), the nuclear receptor involved in the regulation of cytochrome P450 3A4 (CYP3A4). Rifampicin forms several degradation products and metabolites of which 25-desacetylrifampicin is the most abundant in vivo. Here, we aimed to study both the stability and metabolism of rifampicin in media and 2D and 3D primary human hepatocytes (PHHs). Additionally, we analyzed interactions of rifampicin derivatives with PXR. We described that rifampicin gradually degrades by more than 50 % in the medium partly into quinone over 72 h. We observed 25-desacetylrifampicin in 2D PHHs but not in 3D PHHs. Contrary, rifampicin was converted into quinone in a one-direction process in media of 3D PHHs. The potency of rifampicin and its derivatives to activate human PXR was arranged as follows: 3-formylrifamycin SV > rifampicin quinone > rifampicin > rifampicin N-oxide > 25-desacetylrifampicin, respectively, but none activates mouse and rat PXR. The binding differences between rifampicin and 25-desacetylrifampicin were modeled in silico. Finally, we showed that overexpressed uptake organic anion transporting polypeptide 1B1 (OATP1B1) potentiated activation of PXR by rifampicin and rifampicin quinone, but overexpressed efflux multidrug resistance protein 1 (MDR1) decreased PXR activation by all derivatives.
Files
1-s2.0-S0006295224004830-main.pdf
Files
(5.2 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:57d73929ab09ea1e1d4a178ada9c537f
|
5.2 MB | Preview Download |
Additional details
Related works
- Is published in
- Journal: 10.1016/j.bcp.2024.116500 (DOI)
- Is supplemented by
- Dataset: https://zenodo.org/records/13737560 (URL)
Funding
- Ministry of Education Youth and Sports
- NETPHARM CZ.02.01.01/00/22_008/0004607
- Czech Science Foundation
- 22-05167S
- Charles University
- Primus 110/13/221301
Dates
- Available
-
2024-08-22
References
- Biochem Pharmacol . 2024 Aug 22:229:116500. doi: 10.1016/j.bcp.2024.116500.